From the FDA Drug Label
The dosing information for INGREZZA is not explicitly stated in the provided text, but the available doses are mentioned: Each capsule contains 73 mg, 109 mg or 146 mg of valbenazine tosylate equivalent to 40 mg, 60 mg or 80 mg of valbenazine free base, respectively.
The dosing for Ingrezza (valbenazine) is 40 mg, 60 mg, or 80 mg of valbenazine free base, with no explicit dosing instructions provided in the label.
- The label does mention that dosage reduction is recommended for known CYP2D6 poor metabolizers and for patients with moderate or severe hepatic impairment.
- However, the label does not provide specific dosing instructions, and the exact dosing may depend on individual patient factors and clinical judgment 1.
From the Research
The recommended dosing for Ingrezza (valbenazine) is 40 mg once daily for the first week, followed by an increase to 80 mg once daily thereafter, as supported by the most recent and highest quality study 2. This medication is taken orally, with or without food.
- For patients who may need a lower dose or have moderate to severe hepatic impairment, a 40 mg daily maintenance dose can be considered.
- The maximum recommended dose is 80 mg once daily. Ingrezza should be taken at approximately the same time each day to maintain consistent blood levels.
- If a dose is missed, the patient should take the next dose at the regular time the following day. It's essential to note that Ingrezza is used for the treatment of tardive dyskinesia in adults, as studied in 2.
- The gradual dose titration helps minimize potential side effects while allowing the medication to reach therapeutic levels.
- The once-daily dosing regimen is designed to improve patient adherence, as discussed in 3 and 4. Patients should be monitored for effectiveness and any adverse reactions, as reported in 5 and 6.
- Dose adjustments may be necessary based on individual response and tolerability. Always consult with a healthcare provider before making any changes to the dosing regimen, considering the findings from 2, which demonstrated the efficacy and safety of valbenazine in treating tardive dyskinesia.